Outcomes following Serial Intragastric Balloon Therapy for Obesity and Nonalcoholic Fatty Liver Disease in a Single Centre

• Published in: Canadian journal of gastroenterology & hepatology Vol. 2017; no. 2017; pp. 1 - 8
• Main Authors: Oben, Jude A., Solis-Cuevas, Alessandro, Ray, Shuvra, Cordero, Paul, Gan, Jaslyn, Li, Jiawei, Nguyen, Vi, Khatib, Mai
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2017; Hindawi; Hindawi Limited
• Subjects: Adult; Anesthesia; Biochemistry; Body mass index; Care and treatment; Chronic illnesses; Endoscopy; Fatty liver; Female; Gastric Balloon; Gastrointestinal surgery; Hepatology; Homeostasis; Hospitals; Humans; Insulin; Insulin resistance; Lifestyles; Liver - physiopathology; Liver diseases; Liver Function Tests; Male; Metabolic syndrome; Methylene blue; Middle Aged; Non-alcoholic Fatty Liver Disease - physiopathology; Non-alcoholic Fatty Liver Disease - surgery; Nutrition research; Obesity; Obesity - physiopathology; Obesity - surgery; Patient outcomes; Patients; Retrospective Studies; Statistical analysis; Systematic review; Therapy; Treatment Outcome; Type 2 diabetes; University colleges; Weight control; London England
• ISSN: 2291-2789; 2291-2797
• DOI: 10.1155/2017/4697194

Background. The incidence of nonalcoholic fatty liver disease (NAFLD) continues to parallel the rise in obesity rates. Endobariatric devices such as the intragastric balloon (IGB) may provide an alternative treatment option. Methods. Outcomes following IGB treatment in 135 patients with obesity and NAFLD (mean baseline weight 117.9 kg; BMI 41.7 kg/m2; HOMA-IR 3.6) were retrospectively examined. Clinical, anthropometric, and biochemical changes were analysed at six months and after consecutive treatment with two and three serial IGBs. Results. After six months, significant changes were seen with weight and BMI (mean reductions of 11.3 kg and 4.1 kg/m2, resp., p<0.01 for both). Significant improvements were also seen with ALT, GGT, and HOMA-IR, with all changes corresponding with weight loss. Forty-eight patients received two IGBs, and 20 were treated with three serial IGBs. The greatest amount of total weight loss was observed after the first 6 months (mean weight lost 7.4 kg, versus 3.6 kg and 1.9 kg with two and three IGBs, resp.). Conclusions. IGB therapy is an effective, alternative nonsurgical means for weight loss in the management of obesity and NAFLD over the short term, with greatest outcomes observed after six months. Improvements in insulin resistance and hepatic transaminases correlated with weight change.